Levosimendan vs placebo
All‐cause long‐term mortality: range 4 to 6 months · adults with cardiogenic shock or low cardiac output syndrome
It is very uncertain whether levosimendan changes all‐cause long‐term mortality: range 4 to 6 months compared with placebo (very low certainty).
1 finding from 1 review
- Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes onlyRR 0.55 [0.16, 1.9]2 studies · 55 participantsVery low